These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 17948981)

  • 1. Highly potent, water soluble benzimidazole antagonist for activated alpha 4 beta 1 integrin.
    Carpenter RD; Andrei M; Lau EY; Lightstone FC; Liu R; Lam KS; Kurth MJ
    J Med Chem; 2007 Nov; 50(23):5863-7. PubMed ID: 17948981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selectively targeting T- and B-cell lymphomas: a benzothiazole antagonist of alpha4beta1 integrin.
    Carpenter RD; Andrei M; Aina OH; Lau EY; Lightstone FC; Liu R; Lam KS; Kurth MJ
    J Med Chem; 2009 Jan; 52(1):14-9. PubMed ID: 19072684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity relationship studies of a series of peptidomimetic ligands for alpha(4) beta(1) integrin on Jurkat T-leukemia cells.
    Liu R; Peng L; Han H; Lam KS
    Biopolymers; 2006; 84(6):595-604. PubMed ID: 17041919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benzimidazole-substituted (3-phenoxypropyl)amines as histamine H3 receptor ligands.
    Aslanian R; Zhu X; Vaccaro HA; Shih NY; Piwinski JJ; Williams SM; West RE
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5032-6. PubMed ID: 18752952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combinatorial chemistry identifies high-affinity peptidomimetics against alpha4beta1 integrin for in vivo tumor imaging.
    Peng L; Liu R; Marik J; Wang X; Takada Y; Lam KS
    Nat Chem Biol; 2006 Jul; 2(7):381-9. PubMed ID: 16767086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of alpha(4)beta(1) (CD49d/CD29) on equine leukocytes: potential utility of a potent alpha(4)beta(1) (CD49d/CD29) receptor antagonist in the treatment of equine heaves (recurrent airway obstruction).
    Treonze KM; Alves K; Fischer P; Hagmann WK; Hora D; Kulick A; Vakerich K; Smith ND; Lingham RB; Maniar S; Reger TS; Zunic J; Munoz B; Prasit P; Nicholson D; Si Q; Judd K; Nicolich S; Kellerhouse P; Thompson D; Mumford RA
    Vet Immunol Immunopathol; 2009 Jul; 130(1-2):79-87. PubMed ID: 19250687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, syntheses, and structure-activity relationships of novel NPY Y5 receptor antagonists: 2-{3-Oxospiro[isobenzofuran-1(3H),4'-piperidin]-1'-yl}benzimidazole derivatives.
    Ogino Y; Ohtake N; Nagae Y; Matsuda K; Moriya M; Suga T; Ishikawa M; Kanesaka M; Mitobe Y; Ito J; Kanno T; Ishihara A; Iwaasa H; Ohe T; Kanatani A; Fukami T
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5010-4. PubMed ID: 18723347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyridone derivatives as potent and selective VLA-4 integrin antagonists.
    Witherington J; Bordas V; Gaiba A; Green PM; Naylor A; Parr N; Smith DG; Takle AK; Ward RW
    Bioorg Med Chem Lett; 2006 Apr; 16(8):2256-9. PubMed ID: 16455247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly water-soluble prodrugs of anthelmintic benzimidazole carbamates: synthesis, pharmacodynamics, and pharmacokinetics.
    Chassaing C; Berger M; Heckeroth A; Ilg T; Jaeger M; Kern C; Schmid K; Uphoff M
    J Med Chem; 2008 Mar; 51(5):1111-4. PubMed ID: 18271517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Halogenated benzimidazole carboxamides target integrin alpha4beta1 on T-cell and B-cell lymphomas.
    Carpenter RD; Natarajan A; Lau EY; Andrei M; Solano DM; Lightstone FC; Denardo SJ; Lam KS; Kurth MJ
    Cancer Res; 2010 Jul; 70(13):5448-56. PubMed ID: 20530664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of acid surrogates toward potency of VLA-4 antagonist.
    Venkatraman S; Lim J; Cramer M; Gardner MF; James J; Alves K; Lingham RB; Mumford RA; Munoz B
    Bioorg Med Chem Lett; 2005 Sep; 15(18):4053-6. PubMed ID: 16039122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and cytotoxicity evaluation of some benzimidazole-4,7-diones as bioreductive anticancer agents.
    Gellis A; Kovacic H; Boufatah N; Vanelle P
    Eur J Med Chem; 2008 Sep; 43(9):1858-64. PubMed ID: 18222567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benzimidazole derivatives as novel nonpeptide luteinizing hormone-releasing hormone (LHRH) antagonists. Part 2: Benzimidazole-5-sulfonamides.
    Li Y; Kataoka M; Tatsuta M; Yasoshima K; Yura T; Urbahns K; Kiba A; Yamamoto N; Gupta JB; Hashimoto K
    Bioorg Med Chem Lett; 2005 Feb; 15(3):805-7. PubMed ID: 15664861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioisosteric replacement of anilide with benzoxazole: potent and orally bioavailable antagonists of VLA-4.
    Lin LS; Lanza TJ; Castonguay LA; Kamenecka T; McCauley E; Van Riper G; Egger LA; Mumford RA; Tong X; MacCoss M; Schmidt JA; Hagmann WK
    Bioorg Med Chem Lett; 2004 May; 14(9):2331-4. PubMed ID: 15081035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological evaluation of novel pyridazinone-based alpha4 integrin receptor antagonists.
    Gong Y; Barbay JK; Dyatkin AB; Miskowski TA; Kimball ES; Prouty SM; Fisher MC; Santulli RJ; Schneider CR; Wallace NH; Ballentine SA; Hageman WE; Masucci JA; Maryanoff BE; Damiano BP; Andrade-Gordon P; Hlasta DJ; Hornby PJ; He W
    J Med Chem; 2006 Jun; 49(11):3402-11. PubMed ID: 16722660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Towards the synthesis of new benzimidazolone derivatives with surfactant properties.
    Lakhrissi B; Benksim A; Massoui M; Essassi el M; Lequart V; Joly N; Beaupère D; Wadouachi A; Martin P
    Carbohydr Res; 2008 Feb; 343(3):421-33. PubMed ID: 18155683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Syntheses and structure-activity relationships of novel, potent, and selective trans-2-[3-oxospiro[isobenzofuran-1(3H),1'-cyclohexan]-4'-yl]benzimidazole NPY Y5 receptor antagonists.
    Ogino Y; Ohtake N; Nagae Y; Matsuda K; Ishikawa M; Moriya M; Kanesaka M; Mitobe Y; Ito J; Kanno T; Ishihara A; Iwaasa H; Ohe T; Kanatani A; Fukami T
    Bioorg Med Chem Lett; 2008 Sep; 18(18):4997-5001. PubMed ID: 18752943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of alpha4beta1 integrin to the antiallergic effect of levocabastine.
    Qasem AR; Bucolo C; Baiula M; Spartà A; Govoni P; Bedini A; Fascì D; Spampinato S
    Biochem Pharmacol; 2008 Sep; 76(6):751-62. PubMed ID: 18680729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New benzimidazoles as thrombopoietin receptor agonists.
    Safonov IG; Heerding DA; Keenan RM; Price AT; Erickson-Miller CL; Hopson CB; Levin JL; Lord KA; Tapley PM
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1212-6. PubMed ID: 16376078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of small molecule benzimidazole antagonists of the chemokine receptor CXCR3.
    Hayes ME; Wallace GA; Grongsaard P; Bischoff A; George DM; Miao W; McPherson MJ; Stoffel RH; Green DW; Roth GP
    Bioorg Med Chem Lett; 2008 Mar; 18(5):1573-6. PubMed ID: 18242988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.